Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

详细信息    查看全文

• 作者：Franck Morschhauser (1) (5)
  Louis Terriou (1)
  Bertrand Coiffier (2)
  Emmanuel Bachy (2)
  Andrea Varga (3)
  Ioana Kloos (4)
  H茅l猫ne Leli猫vre (4)
  Anne-Laure Sarry (4)
  St茅phane Depil (4)
  Vincent Ribrag (3)
  
  1. Centre Hospitalier R茅gional de Lille ; H么pital Claude Huriez ; Service des maladies du sang ; Groupe de Recherche sur les formes Injectables et les Technologies Associ茅es (GRITA) ; Universit茅 de Lille ; Lille ; France
  5. Centre Hospitalier R茅gional de Lille ; H么pital Claude Huriez ; 1 rue Michel Polonovski ; 59037 ; Lille ; Cedex ; France
  2. Centre Hospitalier Lyon Sud ; Service d鈥檋茅matologie ; Pierre B茅nite ; France
  3. Institut de Canc茅rologie Gustave Roussy ; SITEP/Service D鈥檋茅matologie ; Villejuif ; France
  4. Oncology R&D Unit ; Institut de Recherches Internationales Servier ; Suresnes ; France
  
• 关键词：Abexinostat ; Lymphoma ; Phase 1 study ; Safety ; Efficacy
• 刊名：Investigational New Drugs
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：33
• 期：2
• 页码：423-431
• 全文大小：754 KB
• 参考文献：1. Bolden, JE, Peart, MJ, Johnstone, RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: pp. 769-784 CrossRef
  2. Ververis, K, Hiong, A, Karagiannis, TC, Licciardi, PV (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7: pp. 47-60
  3. Glass, E, Viale, PH (2013) Histone deacetylase inhibitors: novel agents in cancer treatment. Clin J Oncol Nurs 17: pp. 34-40 CrossRef
  4. Richon, VM, Garcia-Vargas, J, Hardwick, JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280: pp. 201-210 CrossRef
  5. Mann, BS, Johnson, JR, Cohen, MH, Justice, R, Pazdur, R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: pp. 1247-1252 CrossRef
  6. Coiffier, B, Pro, B, Prince, HM, Foss, F, Sokol, L, Greenwood, M (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30: pp. 631-636 CrossRef
  7. Watanabe, T (2010) Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs 19: pp. 1113-1127 CrossRef
  8. Buglio, D, Younes, A (2010) Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs 28: pp. S21-S27 CrossRef
  9. Veliz, M, Pinilla-Ibarz, J (2012) Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control 19: pp. 37-53
  10. Lopez, G, Liu, J, Ren, W, Wei, W, Wang, S, Lahat, G (2009) Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 15: pp. 3472-3483 CrossRef
  11. Buggy, JJ, Cao, ZA, Bass, KE, Verner, E, Balasubramanian, S, Liu, L (2006) CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5: pp. 1309-1317 CrossRef
  12. Rivera-Del VN, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M et al (2010) PCI-24781, a novel hydroxamic Acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells. Int J Cell Biol 207420
  13. Yang, C, Choy, E, Hornicek, FJ, Wood, KB, Schwab, JH, Liu, X (2011) Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol 67: pp. 439-446 CrossRef
  14. Yang, C, Choy, E, Hornicek, FJ, Wood, KB, Schwab, JH, Liu, X (2011) Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res 31: pp. 1115-1123
  15. National Cancer Institute. Common terminology criteria for adverse events. Version 3.0. NCI 2006; http://ctep.cancer.gov. Accessed 2-4-2013.
  16. Oken, MM, Creech, RH, Tormey, DC, Horton, J, Davis, TE, McFadden, ET (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: pp. 649-655 CrossRef
  17. Cheson, BD, Pfistner, B, Juweid, ME, Gascoyne, RD, Specht, L, Horning, SJ (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: pp. 579-586 CrossRef
  18. Hallek, M, Cheson, BD, Catovsky, D, Caligaris-Cappio, F, Dighiero, G, Dohner, H (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: pp. 5446-5456 CrossRef
  19. Fouliard, S, Robert, R, Jacquet-Bescond, A, Rieu, QC, Balasubramanian, S, Loury, D (2013) Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. Eur J Cancer 49: pp. 2791-2797 CrossRef
  20. EMA Oncology Working Party. Guideline on the evaluation of anticancer medicinal products in man. European Medicines Agency 2010; www.ema.europa.eu. Accessed 30-9-2013
  21. Fouliard S, Chenel M. BSA-adjusted dose? An old method to fight old bias. Poster presented at the Population Approach Group Europe meeting 2010. PAGE 2010; www.page-meeting.org. Accessed 30-9-2013
  22. Evens AM, Vose JM, Harb W, Gordon LI, Langdon R, Grant B et al. A phase II multicenter study of the histone deactelase inhibitor abexinostat (PCI-24781) in relapsed/refractory follicular lymphoma (FLp and mantle cell lymphoma (MCL). Abstract 55. Blood 2013; 120 (Suppl)
  23. Green, MR, Gentles, AJ, Nair, RV, Irish, JM, Kihira, S, Liu, CL (2013) Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121: pp. 1604-1611 CrossRef
  24. Okosun, J, Bodor, C, Wang, J, Araf, S, Yang, CY, Pan, C (2014) Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46: pp. 176-181 CrossRef
  25. Munster, PN, Thurn, KT, Thomas, S, Raha, P, Lacevic, M, Miller, A (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104: pp. 1828-1835 CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Pharmacology and Toxicology
  
• 出版者：Springer Netherlands
• ISSN：1573-0646

文摘